EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection

Inderjit Mehmi, Jonathan E Cohen, Kathryn Bollin, Siwen Hu-Lieskovan, Adam Dugan, Binyam Yilma, Stamatina Fragkogianni, Unnati Jariwala, Jacob Mercer, Omid Hamid

The Oncologist · 12.11.2026

DOI: 10.1093/oncolo/oyag441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 12.11.2026. Verfasst von Inderjit Mehmi und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple first-line immune checkpoint regimens are approved for advanced melanoma, yet no biomarker reliably guides their selection. LAG-3, an inhibitory checkpoint enriched on exhausted immune cells, may reflect tumor–immune state beyond PD-L1 and guide therapeutic decisions Methods We retrospectively analyzed Tempus platform data . Among 2,177 patients with advanced melanoma and RNA sequencing, 145 received first-line PD-1 monotherapy and 222 CTLA-4/PD-1 combination. LAG3 and CD274 (PD-L1) transcript levels were evaluated as dichotomous variables. Outcomes included objective response rate (ORR) at 90 days and real-world overall survival (rwOS). We assessed treatment–biomarker (LAG3/CD274) interactions and performed statistical de-correlation and fit treatment-specific multivariable Cox models including LAG3 expression, CD274 expression, and estimated CD8 T-cell infiltration . We also explored LAG3 association with immune infiltrate, tumor mutation - and neoantigen-burdens.

Results

Under monotherapy, high LAG-3 was associated with improved outcomes, ORR (67% vs 15%, p = 0.002); risk of death (HR 0.64; p < 0.001). In contrast, ORR and risk of death were similar for the combination cohort regardless of LAG-3 expression (HR 0.94, p = 0.6). After de-correlation, LAG-3 retained significant association with rwOS under monotherapy, whereas the association for CD274 was attenuated, indicating non-redundant biomarker information. In multivariable Cox analysis including continuous LAG3, CD274, and estimated CD8 T-cell infiltration, LAG3 remained independently associated with improved rwOS in the PD-1 monotherapy cohort (HR 0.54, 95% CI 0.32-0.91; p = 0.021), whereas neither CD274 nor CD8 infiltration remained significant. No biomarker significantly discriminated outcomes within the combination therapy cohort.

Conclusions

These findings support further validation of LAG3 RNA expression as a candidate biomarker for frontline immunotherapy selection in advanced melanoma.

Schlagwörter

Stichwörter der Autor:innen

BiomarkersCTLA-4 blockadeImmune checkpoint inhibitorsLymphocyte Activation Gene-3 (LAG-3, CD223)Malignant melanomaPD-1 blockade

Autor:innen und Institutionen

  • The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA.
  • Sharett Institute of Oncology, Hadassah Cancer Research Institute and The Wohl Institute for Translational Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Department of Hematology and Oncology, Scripps Cancer Center, San Diego, CA.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • Tempus AI, Inc., Chicago, IL.

Zitieren

APA

Mehmi, I., Cohen, J. E., Bollin, K., Hu-Lieskovan, S., Dugan, A., Yilma, B., Fragkogianni, S., Jariwala, U., Mercer, J., & Hamid, O. (2026). Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection. The Oncologist. https://doi.org/10.1093/oncolo/oyag441

Vancouver

Mehmi I, Cohen JE, Bollin K, Hu-Lieskovan S, Dugan A, Yilma B, et al. Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection. The Oncologist. 2026. doi:10.1093/oncolo/oyag441

BibTeX
@article{Mehmi2026,
  author = {Mehmi, Inderjit and Cohen, Jonathan E and Bollin, Kathryn and Hu-Lieskovan, Siwen and Dugan, Adam and Yilma, Binyam and Fragkogianni, Stamatina and Jariwala, Unnati and Mercer, Jacob and Hamid, Omid},
  title = {Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag441}
}
Kostenlos starten →